Navigation Links
Pinnacle Biologics Announces Logistics Services Agreement With the Movianto Group

ROCKVILLE, Md., June 17 /PRNewswire/ -- Pinnacle Biologics, a private, full-service pharmaceutical and biotech solutions company, today announced it has entered into a logistic service agreement with Movianto, a German-based company. The agreement, which is scheduled to take effect immediately, grants Movianto certain logistics and distribution rights in several countries in Europe. Additional terms of the agreement were not disclosed.

"The agreement with Movianto represents another milestone in Pinnacle's infrastructure and further showcases our vast capability to assist large pharmaceutical and biotechnology companies in optimizing the international market potential of mature products without diversion of resources from core businesses," said Guillermo Herrera, chairman of the board of Pinnacle Biologics. "Additionally, the Pinnacle business model is optimal for small biotechnology that require a total solution from pre-launch to commercialization of products."

Conor Roche, managing director of the Movianto Group commented: "Movianto is extremely excited about expanding our service portfolio to meet Pinnacle's unique distribution and logistics requirements and to accelerate the commercialization of the Pinnacle business model in Europe."

About Pinnacle Biologics

Founded in 2007 by health care executives Guillermo Herrera, James Miller, and Viren Grover, Pinnacle Biologics is a premier international company that excels in assisting pharmaceutical and biotech companies that require a total solution in either launching products or maximizing/monetizing the value of products late in their life cycle. Pinnacle forms exclusive relationships with research-based pharmaceutical multi-national corporations and biotechnology companies to take products to the next level.

Pinnacle provides a full range of services including regulatory, sales, marketing, distribution (including billing and collections), pharmacovigilence, product safety, market research and administrative services.

About Movianto

Movianto provides the pharmaceutical, biotechnology and healthcare industry with innovative logistics and distribution solutions across Europe. Movianto's 400 international clients, including the world's ten largest pharmaceutical manufacturers, benefit from a broad range of pharmaceutical logistics services and the variety of distribution models at national, regional and European level. Movianto is a business unit of Celesio AG. For further information, please visit

SOURCE Pinnacle Biologics
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Specialists Are Turning to Biologics Earlier in the Treatment of Psoriasis and Psoriatic Arthritis
2. Nabi Biopharmaceuticals Announces Sale of Nabi Biologics to Biotest AG
3. AstraZeneca Bolsters Its Worldwide Biologics Division Through Integration of Cambridge Antibody Technology Into MedImmune
4. Biotest Pharmaceuticals Corporation Completes Acquisition of Nabi Biologics Business Unit
5. Kendle Appoints Former MHRA Head of Biologics as Principal Regulatory Affairs Consultant
6. Insmed President Interviewed for Follow-On Biologics Podcast: Insmed Inc. President Steve Glover Discusses Safe and Effective Biologic Therapies and Reduced Costs with The American Magazine
7. MedImmune Submits Biologics License Application to FDA for Motavizumab
8. Insmed CEO Issues Statement on White House FY09 Budget and FDA Statements on Follow-On Biologics
9. Study by Leading Economist Identifies Potential for $378 Billion of Savings From Follow On Biologics
10. Biologics, Derma Fillers are Key to Dermatological Drug Market Growth
11. Insmed Selected to Complete Congressional Questionnaire Regarding the Potential Establishment of a Follow-On Biologics Regulatory Pathway
Post Your Comments:
(Date:11/25/2015)... , Nov. 25, 2015  PharmAthene, Inc. (NYSE ... has adopted a stockholder rights plan (Rights Plan) in ... operating loss carryforwards (NOLs) under Section 382 of the ... --> PharmAthene,s use of its NOLs could ... change" as defined in Section 382 of the Code. ...
(Date:11/25/2015)... 25, 2015 Studies reveal the ... plaque and pave the way for more effective treatment for ...     --> --> ... health problems in cats, yet relatively little was understood about ... studies have been conducted by researchers from the WALTHAM Centre ...
(Date:11/25/2015)... , Nov. 25, 2015  Neurocrine Biosciences, Inc. (Nasdaq: ... , President and CEO of Neurocrine Biosciences, will be ... in New York . ... the website approximately 5 minutes prior to the presentation ... of the presentation will be available on the website ...
(Date:11/25/2015)... ... November 25, 2015 , ... A long-standing ... Aerospace Professionals (OPBAP) has been formalized with the signing of a Memorandum of ... with OPBAP leaders Capt. Karl Minter and Capt. Albert Glenn Tuesday, November 24, ...
Breaking Biology Technology:
(Date:11/17/2015)... PARIS , November 17, 2015 ... November 2015.   --> Paris from ... --> DERMALOG, the biometrics innovation leader, has invented the ... and fingerprints on the same scanning surface. Until now two ... fingerprints. Now one scanner can capture both on the same ...
(Date:11/17/2015)... EASTON, Mass. , Nov. 17, 2015 ... a leader in the development and sale of broadly ... the worldwide life sciences industry, today announced it has ... of its $5 million Private Placement (the "Offering"), increasing ... to $4,025,000.  One or more additional closings are expected ...
(Date:11/12/2015)... Mass. , Nov. 12, 2015  Arxspan ... Institute of MIT and Harvard for use of ... discovery information management tools. The partnership will support ... both biological and chemical research information internally and ... will be used for managing the Institute,s electronic ...
Breaking Biology News(10 mins):